Anavex Life Sciences Corp (AVXL)

[kund]

Another puff PR in the series of PRs. Christopher need to come out with solid PR like SAVA. SAVA was able to recruits 650 patients in under one year, but for Misleading it took 2 1/2 year to recruit 500 patient.

In October and November 2021, we announced initiation of our two Phase 3 studies of simufilam, respectively. As of November 2, 2022, a total of over 650 subjects have been enrolled in the Phase 3 program. Patients are now being screened in clinical trial sites in the U.S., Canada, Puerto Rico, Australia, and South Korea.